Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Manager /cta /qa Admin
- in****@****hem.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aptahem.com
Aptahem Questions
Aptahem's website is aptahem.com
Aptahem's LinkedIn profile is https://se.linkedin.com/company/aptahem
Aptahem has
6 employees.
View email and phone details for 6
employees at Aptahem.
Aptahem's industry is
Biotechnology Research
Aptahem's top competitors are
Atlas Antibodies,
Coegin Pharma Ab,
Idl Diagnostics Ab (Idldx),
Atmp Sweden,
Nextcell Pharma Ab,
Abliva Ab,
Annexin Pharmaceuticals Ab (Publ),
Ascelia Pharma Ab,
Cellevate Ab,
Acucort Ab.
Aptahem's support email address is info@aptahem.com
Aptahem's categories are Biotechnology Research
Aptahem's founding year is 2014
